1. Home /
  2. Biotechnology

Biotechnology

Insys Therapeutics Sinks After Filing for Bankruptcy

Insys Therapeutics Sinks After Filing for Bankruptcy

Insys says it will continue to operate its business 'in the ordinary course' while it sells off its assets through bankruptcy court.

Blindly Following the Consensus Is Rarely the Right Course of Action

Blindly Following the Consensus Is Rarely the Right Course of Action

That's why I always act incrementally when allocating new funds to the market or raising cash in my portfolio.

Stalking Entry Points in the XBI Biotech ETF

Stalking Entry Points in the XBI Biotech ETF

Plus an update on my SPX and Nike plays.

Mirati Therapeutics Could Soar Even Higher

Mirati Therapeutics Could Soar Even Higher

Prices went vertical early this month on heavy volume.

Google's $2.6-Billion Deal for Looker Drives Home Its Big Cloud Ambitions

Google's $2.6-Billion Deal for Looker Drives Home Its Big Cloud Ambitions

While Looker operates in a very competitive market, it does have some unique technology strengths that could be useful as Google tries to grow its enterprise cloud position.

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction

Eli Lilly's plan to eliminate pain could have farther reaching positive effects than just migraines.

Here's How Anxious Investors Can Hedge Against Fed Uncertainty

Here's How Anxious Investors Can Hedge Against Fed Uncertainty

The Fed has given retail investors a run around in the past year. Here's the game-plan from here.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Amgen Shares Gain on Positive Lung-Cancer Trial Results

Shares of Amgen rise after the company announces positive initial trial results from its experimental drug used to treat non-small-cell lung cancer patients.